Celyad Receives Additional EUR2.5 Million in Non-Dilutive Funding
(WorldNews Belgium)

Celyad Receives Additional EUR2.5 Million in Non-Dilutive Funding 06 Dec 2019 07:33 CET Company Name CELYAD ISN BE0974260896 Market Euronext Symbol CYAD Regulatory News: Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that the Company has received EUR2.5 million in non-dilutive funding. The amount is comprised of EUR2.1 million in non-dilutive funding from the SPW-Recherche of the Walloon Region, which will support the development of the company`s CAR-T candidates for the treatment of solid tumors, and EUR0.4 million of non-refundable tax incentive from Belgian Public Health...